| Year |
Citation |
Score |
| 2020 |
Wander SA, Cohen O, Gong X, Johnson GN, Buendia-Buendia J, Lloyd M, Kim D, Luo F, Mao P, Helvie K, Kowalski K, Nayar U, Parsons S, Martinez R, Litchfield L, ... ... Wagle N, et al. Abstract PD2-09: The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC) Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Pd2-09 |
0.306 |
|
| 2020 |
Wander S, Mao P, Lloyd M, Kowalski K, Johnson GN, Malvarosa G, Moy B, Ellisen LW, Iafrate J, Wagle N, Bardia A. Abstract P6-10-08: AKT1 alterations following exposure to endocrine-based therapy in patients with hormone-receptor positive (HR+) metastatic breast cancer (MBC): Clinical and functional implications Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P6-10-08 |
0.335 |
|
| 2020 |
Nayar U, Piccioni F, Yang X, Root D, Neal JT, Eli LD, Diala I, Lalani AS, Wagle N. Abstract 1914: Phenotypic characterization of a comprehensive set of HER2 missense mutants in ER+ breast cancer Cancer Research. 80: 1914-1914. DOI: 10.1158/1538-7445.Am2020-1914 |
0.305 |
|
| 2019 |
Jain E, Kim D, Buendia J, Cohen O, Sousa R, Anastasio E, Dunphy M, McGillicuddy M, Stoddard R, Balch S, Thomas B, Lascio SD, Tomson B, Nguyen C, Painter C, ... Wagle N, et al. Abstract PD9-03: The genomic landscape of de novo metastatic breast cancer (MBC) Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Pd9-03 |
0.322 |
|
| 2018 |
Stover DG, Parsons HA, Ha G, Freeman SS, Barry WT, Guo H, Choudhury AD, Gydush G, Reed SC, Rhoades J, Rotem D, Hughes ME, Dillon DA, Partridge AH, Wagle N, et al. Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017760033. PMID 29298117 DOI: 10.1200/Jco.2017.76.0033 |
0.306 |
|
| 2018 |
Mo SS, Liu D, Gray SW, Joffe S, Wagle N, Garber J, Garraway LA, Sholl L, Janne PA, Allen EMV. Abstract 3254: Dissecting genomic determinants of response to platinum-based chemotherapy in advanced NSCLC and colorectal cancer Cancer Research. 78: 3254-3254. DOI: 10.1158/1538-7445.Am2018-3254 |
0.316 |
|
| 2017 |
Giltnane JM, Hutchinson KE, Stricker TP, Formisano L, Young CD, Estrada MV, Nixon MJ, Du L, Sanchez V, Ericsson PG, Kuba MG, Sanders ME, Mu XJ, Van Allen EM, Wagle N, et al. Genomic profiling of ER(+) breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. Science Translational Medicine. 9. PMID 28794284 DOI: 10.1126/Scitranslmed.Aai7993 |
0.307 |
|
| 2017 |
Cohen O, Kim D, Oh C, Waks A, Oliver N, Helvie K, Marini L, Rotem A, Lloyd M, Stover D, Adalsteinsson V, Freeman S, Ha G, Cibulskis C, Anderka K, ... ... Wagle N, et al. Abstract S1-01: Whole exome and transcriptome sequencing of resistant ER+ metastatic breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-S1-01 |
0.329 |
|
| 2017 |
Nayar U, Cohen O, Oh C, Wagle N. Abstract P3-04-08: The role of HER2 mutations in resistance to endocrine therapy in ER+ breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P3-04-08 |
0.32 |
|
| 2016 |
Wagle N, Painter C, Ilzarbe M, Allen EV, Frank E, Oh C, Krevalin M, Lloyd M, Anderka K, Kryukov G, Boehm J, Winer E, Lander E, Golub T. Abstract OT2-05-03: The metastatic breast cancer project: A national direct-to-patient research initiative to accelerate genomics research Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-Ot2-05-03 |
0.307 |
|
| 2016 |
Adalsteinsson VA, Ha G, Freeman S, Choudhury AD, Stover DG, Parsons HA, Gydush G, Reed S, Loginov D, Livitz D, Rosebrock D, Leshchiner I, Cohen O, Oh C, Kim J, ... ... Wagle N, et al. Abstract LB-136: High concordance of whole-exome sequencing of cell-free DNA and matched biopsies enables genomic discovery in metastatic cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-136 |
0.325 |
|
| 2015 |
Stover DG, Wagle N. Precision medicine in breast cancer: genes, genomes, and the future of genomically driven treatments. Current Oncology Reports. 17: 15. PMID 25708799 DOI: 10.1007/S11912-015-0438-0 |
0.307 |
|
| 2015 |
Grabiner B, Wagle N, Allen EV, Garraway L, Lorch J, Sabatini D. Abstract PR04: mTOR mutations in cancer Molecular Cancer Therapeutics. 14. DOI: 10.1158/1538-8514.Pi3K14-Pr04 |
0.307 |
|
| 2014 |
Wagle N, Lin NU, Richardson AL, Leshchiner I, Mayer IA, Forero-Torres A, Hobday TJ, Dees EC, Nanda R, Rimawi MF, Guo H, Barry WT, Wolff AC, Gabriel SB, Garraway LA, et al. Whole-exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients (pts) treated with prior trastuzumab (T): A correlative analysis of TBCRC003. Journal of Clinical Oncology. 32: 536-536. DOI: 10.1200/Jco.2014.32.15_Suppl.536 |
0.303 |
|
| 2014 |
Wagle N, Grabiner BC, Allen EMV, Amin-Mansour A, Carter SC, Gray N, Barletta JA, Swanson SJ, Ruan D, Kwiatkowski DJ, Hanna GJ, Haddad RI, Sabatini D, Janne PA, Garraway LA, et al. Abstract 1724: Genomic mechanisms of exquisite sensitivity and acquired resistance to everolimus in a patient with anaplastic thyroid carcinoma Cancer Research. 74: 1724-1724. DOI: 10.1158/1538-7445.Am2014-1724 |
0.31 |
|
| 2013 |
Rodon J, Juric D, Gonzalez-Angulo A, Bendell J, Berlin J, Bootle D, Gravelin K, Huang A, Derti A, Lehar J, Würthner J, Boehm M, Allen Ev, Wagle N, Garraway LA, et al. Abstract LB-65: Towards defining the genetic framework for clinical response to treatment with BYL719, a PI3Kalpha-specific inhibitor. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-65 |
0.305 |
|
| 2012 |
Balko JM, Mayer IA, Sanders ME, Miller TW, Kuba MG, Meszoely IM, Wagle N, Garraway LA, Arteaga CL. Discordant cellular response to presurgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification. Molecular Cancer Therapeutics. 11: 2301-5. PMID 22879364 DOI: 10.1158/1535-7163.Mct-12-0511 |
0.304 |
|
| Show low-probability matches. |